Navigation Links
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
Date:8/5/2009

href="http://www.neurogesx.com/" target="_new">http://www.neurogesx.com.

A replay of the conference call will be available beginning August 7, 2009 at 12:00 p.m. ET (9:00 a.m. PT) and ending on August 17, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 329620. A replay of the webcast will also be available on the corporate website for one month, through September 7, 2009.

About NeurogesX, Inc.

NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat p
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
2. NeurogesX Added to Russell 3000 Index
3. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
4. NeurogesX to Present at Needham Life Sciences Conference
5. NeurogesX Receives European Commission Approval for Qutenza(TM)
6. NeurogesX Reports First Quarter 2009 Results
7. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
8. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
9. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
10. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
11. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... the promotions of Linda Arterburn, PhD, Francisco Leon, MD, ... "We are pleased,to announce the promotions of several of ... a fine group of talented people working here to ... with celiac,disease, asthma, eye disorders, and other areas to ...
... Business Update to Investors, WILMINGTON, Del., Oct. ... Vice President & General Manager John Ranieri,said the ... programs to,market are on track and making significant ... conversion of cellulosic feedstocks,economically into biofuels., "Biobutanol ...
... OF PHASE II DATA FOR LEAD DRUG CANDIDATE ... Oct. 2 Transave, Inc., a,biopharmaceutical company focused ... of serious lung diseases,today announced that it has ... and Compass Horizon Funding Company LLC, an affiliate ...
Cached Biology Technology:Alba Therapeutics Corporation Announces Promotions 2Alba Therapeutics Corporation Announces Promotions 3Alba Therapeutics Corporation Announces Promotions 4DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5
(Date:4/24/2014)... and the University of North Carolina at Chapel Hill ... identify arterial plaque that is at high risk of ... At issue is the plaque that builds up in ... deemed "vulnerable," meaning that they are more likely to ... or stroke. , "Existing state-of-the-art technologies are capable of ...
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/23/2014)... data shows Africa,s Congo rainforest, the second-largest tropical rainforest ... greenness over the past decade. , The study, led ... of New York, shows between 2000 and 2012 the ... intensified. The research, published Wednesday in Nature , ... explore the effects of long-term drought on the Congo ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2Two new US turtle species described 2Two new US turtle species described 3NASA satellites show drought may take toll on Congo rainforest 2NASA satellites show drought may take toll on Congo rainforest 3
... The age at which a person takes a first ... drinkers the most susceptible to severe problems. A team ... Medicine in St. Louis, studied 6,257 adult twins from Australia. ... an early age are more likely to develop a more ...
... subsidies to fossil fuels are attributed to tax breaks ... be released on Friday by the Environmental Law Institute ... for Scholars. The study, which reviewed fossil fuel ... the lion,s share of energy subsidies supported energy sources ...
... Hopkins School of Medicine have discovered how one antioxidant ... the development of spinal cord neurons. The research, publishing ... known mechanism of protein control. "This is the ... control neuronal differentiation," says Shanthini Sockanathan, Ph.D., an associate ...
Cached Biology News:Young age at first drink may affect genes and risk for alcoholism 2Young age at first drink may affect genes and risk for alcoholism 3US tax breaks subsidize foreign oil production 2Antioxidant controls spinal cord development 2
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
...
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
Biology Products: